Evidence map›Paper›PMID 28608814›Full record

ArticleInternational journal of molecular sciences2017

Predicting Outcome and Therapy Response in mCRC Patients Using an Indirect Method for CTCs Detection by a Multigene Expression Panel: A Multicentric Prospective Validation Study.

Yolanda Vidal Insua, Juan de la Cámara, Elena Brozos Vázquez, Ana Fernández, Francisca Vázquez Rivera, Mª José Villanueva Villanueva Silva, Jorge Barbazán, Laura Muinelo-Romay, Sonia Candamio Folgar, Alicia Abalo and 3 more

Abstract readMulticenter Study
In one paragraph

Article in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Clusterin Expression in Colorectal Carcinomas.International journal of molecular sciences · 2023
    Review
  7. Review
  8. Methylation detection of circulating tumor cell miR-486-5p/miR-34c-5p in the progression of colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. THBS1 facilitates colorectal liver metastasis through enhancing epithelial-mesenchymal transition.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Article
  14. Article
  15. Review
  16. PrediCTC, liquid biopsy in precision oncology: a technology transfer experience in the Spanish health system.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yolanda Vidal InsuaTranslational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. Yolanda.Vidal.Insua@sergas.es.
Juan de la CámaraArquitecto Macide Hospital, SERGAS Group, Av. Residencia s/n, 15405 Ferrol, Spain. juan.cruz.de.la.camara.gomez@sergas.es.
Elena Brozos VázquezTranslational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. elenambrozosv@hotmail.com.
Ana FernándezUniversity Hospital of Ourense, SERGAS Group, Ramon Puga 54, 32005 Ourense, Spain. afm1003@hotmail.com.
Francisca Vázquez RiveraTranslational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. Francisca.Vazquez.Rivera@sergas.es.
Mª José Villanueva Villanueva SilvaUniversity Hospital of Vigo, SERGAS Group, Pizarro 22, 36204 Vigo, Spain. maria.jose.villanueva.silva@sergas.es.
Jorge BarbazánTranslational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. jorgebarbazan@gmail.com.
Laura Muinelo-RomayTranslational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. lmuirom@gmail.com.
Sonia Candamio FolgarTranslational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. soniasigueiro@yahoo.es.
Alicia AbaloTranslational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. alicia.abalo.pineiro@sergas.es.
Rafael López-LópezTranslational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. Rafael.lopez.lopez@sergas.es.
Miguel AbalTranslational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. miguel.abal.posada@sergas.es.
Lorena Alonso-AlconadaTranslational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. lorena.alonso.alconada@sergas.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is one of the major causes of cancer-related deaths. Early detection of tumor relapse is crucial for determining the most appropriate therapeutic management. In clinical practice, computed tomography (CT) is routinely used, but small tumor changes are difficult to visualize, and reliable blood-based prognostic and monitoring biomarkers are urgently needed. The aim of this study was to prospectively validate a gene expression panel (composed of

Indexed as

Gene Expression Regulation, NeoplasticBiomarkers, TumorColorectal NeoplasmsDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateMaleNeoplasm MetastasisNeoplastic Cells, CirculatingPrognosisProspective StudiesTreatment OutcomeBiomarkers, Tumorbiomarkerscirculating tumor cellsmetastatic colorectal cancertherapy response

Identifiers

PMID28608814
PMCPMC5486087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.